Ataluren was assessed for clinical benefit in patients with DMD/BMD due to nonsense mutation in the dystrophin gene in a Ph2b randomized, double-blind, placebo-controlled study (NCT00592553). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.